Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 5:44 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 5:44 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Why Is Gilead (GILD) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead (GILD) & MRK's HIV Oral Combo Shows Efficacy in Phase II
by Zacks Equity Research
Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
by Zacks Equity Research
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $72.31, marking a +0.29% move from the previous day.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Zacks Analyst Blog Highlights Merck, ServiceNow, Blackstone, Gilead Sciences and Diageo
by Zacks Equity Research
Merck, ServiceNow, Blackstone, Gilead Sciences and Diageo are included in this Analyst Blog.
Top Research Reports for Merck, ServiceNow & Blackstone
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ServiceNow, Inc. (NOW) and Blackstone Inc. (BX).
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
by Zacks Equity Research
Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.
Where Are Biotech ETFs Headed After Q4 Earnings?
by Yashwardhan Jain
Look into how Biotech ETFs performed after Q4 earnings.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
by Zacks Equity Research
Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
Company News for Feb 13, 2024
by Zacks Equity Research
Companies In The Article Are: FANG, JOBY,C, CBAY and GILD
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO
by Zacks Equity Research
Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO are included in this Analyst Blog.
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
by Zacks Equity Research
Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
Company News for Feb 8, 2024
by Zacks Equity Research
Companies in The News Are: ARCC,EMR,F,GILD
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury
by Zacks Equity Research
Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
by Mark Vickery
Markets bounced back this Tuesday from a Monday sell-off, though not all the way back to Friday highs.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Earnings, Fed Speakers Dominate Activity; Lilly Beats, Spotify Misses
by Mark Vickery
Investors of Lilly (LLY) are responding to the eye-opening efficacy of obesity drugs Mounjaro and Zepbound.